Dr Angray Kang, BSc (Hons), PhD
Reader in Molecular Cell Biology
Email: firstname.lastname@example.orgTelephone: +44 (0) 20 7882 7158Room Number: G82, Blizard Building, Institute of Dentistry
1979-1983 Kings (Chelsea College) University of London B.Sc. Microbiology 1st Class Honours.
1983-1986 University of East Anglia Ph.D. Biochemistry (Institute of Food Research Norwich, supervisor Prof. Henry W-S. Chan). The research was supported by an AFRC studentship and directed towards generating antibodies against mycotoxins (aflatoxin & sterigmatocystin) and developing non-isotopic immunoassays.
1986-1987 Post doctoral research (SERC) at University of Durham UK with Professor Don Boulter.
1987-1989 Post doctoral research (SERC) at University of Sheffield UK with Professor Dennis Burton.
1989-1990 Visiting post doctoral researcher at The Scripps Research Institute with Professor Richard A. Lerner.
1990-1999 Assistant Professor Molecular Biology, The Scripps Research Institute.
Between 1999 and the return to academia in 2005 held various posts of increasing responsibility in drug discovery and development in biopharmaceutical companies (Abgenix Inc, Diversa Corporation and Avanir Pharmaceuticals).
2005-2011 Reader in Molecular Applied Biosciences at the University of Westminster.
2011- present Reader in Molecular Cell Biology Queen Mary University of London.
Google Scholar Citations
Achievements in education
Awarded Fellowship of the Higher Education Authority. Supervised PhD, DClinDent, MSc , BSc, iBSc, FY1 and FY2 project students. Developed and rolled out a novel approach to engage students in research via the SSC component in the new BDS curriculum. Participated in delivery of BDS Year1 (Basic Sciences)and Year 3 (SSC), MSc Oral Biology and MSc EOP MSc. Introduced lectures on the potential of therapeutic use of antibodies in dentistry. Co-developed a module with Professor Gareth Sanger on Drug Discovery and Development for the Yearv3 BSc Biomedical Sciences. Active internal PhD progression panel member for PhD students across SMD and SBCS.
Real achievements in researchSelected Publications
Development of transgenic fungi that kill human malaria parasites in mosquitoes. Fang W, Vega-Rodríguez J, Ghosh AK, Jacobs-Lorena M, Kang A, St Leger RJ. Science. 2011 Feb 25;331(6020):1074-7
7 PNAS articles
16 Issued US patents.
Tang J, Wang L, Markiv A, Jeffs SA, Dreja H, McKnight A, He M, Kang AS. Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display. Human Antibodies. 2012 in press.
Azizi A, Arora A, Markiv A, Lampe DJ, Miller T, Kang AS. Ribosome Display of Combinatorial Antibody Libraries Derived From Mice Immunised With Heat-Killed Xylella fastidiosa and the Selection of MopB-Specific Single-Chain Antibodies. Appl Environ Microbiol. 2012 Apr;78(8):2638-47.
Markiv A, Beatson R, Burchell J, Durvasula RV, Kang AS. Expression of recombinant multi-coloured fluorescent antibodies in gor -/ trxB- E. coli cytoplasm. BMC Biotechnol. 2011 Nov 30;11(1):117.
Fang W, Vega-Rodríguez J, Ghosh AK, Jacobs-Lorena M, Kang A, St Leger RJ. Development of transgenic fungi that kill human malaria parasites in mosquitoes. Science. 2011 Feb 25;331(6020):1074-7
Markiv A, Anani B, Durvasula RV, Kang AS. Module based antibody engineering: a novel synthetic REDantibody. J Immunol Methods. 2011 Feb 1;364(1-2):40-9.
Achievements in leadership
Led on the development of a new SSC format for BDS. Led on the development of a novel Anti-Antibody Drug Assay to be used across SMD
Achievements in administration supportAdminister SSC as lead , MSc EOP as lead. Assisted in BDS intake interviews